Mineralys Therapeutics (MLYS) Return on Equity [ROE] (2023 - 2026)
Mineralys Therapeutics' Return on Equity [ROE] was -62.37% in Q2 2026, down 0.37 percentage points from -61.99% a year earlier and down 35.67 percentage points from the prior quarter.
Powered by 
Analysis
Mineralys Therapeutics (MLYS) Return on Equity [ROE] (2023 - 2026) Analysis & Trends
For FY2025, Return on Equity [ROE] at Mineralys Therapeutics came in at -40.72%, up 48.27 percentage points from FY2024.
- In earlier years, Return on Equity [ROE] was -88.99% in FY2024 (+0.65 pp) and -89.64% in FY2023.
- The Q2 2026 figure marks the lowest quarterly Return on Equity [ROE] since Q1 2025.
- Compared with a year earlier, Return on Equity [ROE] was higher in three of the last eight quarters, with an average year-over-year change of -2.50 percentage points.
- The best year-over-year quarter for Return on Equity [ROE] over five years was Q4 2025 (a gain of 61.97 percentage points); the worst was Q4 2024 (a drop of 56.35 percentage points).
- Per Business Quant data, MLYS's Return on Equity [ROE] in the three quarters before Q2 2026 was -26.70% (Q1 2026), -27.90% (Q4 2025) and -41.37% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Mineralys Therapeutics | 2.09 Bn | 2.09 Bn | - | -62.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.37% |
| Mar 31, 2026 | -26.70% |
| Dec 31, 2025 | -27.90% |
| Sep 30, 2025 | -41.37% |
| Jun 30, 2025 | -61.99% |
| Mar 31, 2025 | -75.63% |
| Dec 31, 2024 | -89.87% |
| Sep 30, 2024 | -63.89% |
| Jun 30, 2024 | -43.52% |
| Mar 31, 2024 | -36.92% |
| Dec 31, 2023 | -33.52% |
| Sep 30, 2023 | -24.39% |
| Jun 30, 2023 | -16.56% |
| Mar 31, 2023 | -31.89% |
API Access
Mineralys Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=MLYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "MLYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=MLYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();